Sponsors (18)
Official title: To amend the Controlled Substances Act with respect to fentanyl-related substances, and for other purposes.
Introduced January 31, 2025 by Chris Pappas · Last progress January 31, 2025
The bill sharpens and speeds federal control and enforcement against fentanyl-related substances and creates scientific and procedural pathways for rescheduling and research, but it risks criminalizing legitimate research and low-level handlers, increases mandatory penalties that can widen disparities and incarceration costs, and could leave enforcement gaps for new synthetic opioids.
Law enforcement and prosecutors can better target large-scale importers and traffickers because the bill sets explicit gram thresholds for felony enhancements and clarifies which analogues count toward those thresholds.
Federal agencies and regulated parties gain greater transparency and faster clarity because the Attorney General must publish covered compounds, the DOJ has a 1-year implementation deadline with interim rules allowed, and GAO will review impacts.
Patients with chronic pain and clinicians may gain legitimate medical access to some fentanyl-related drugs if HHS-supported rescheduling leads to Schedule III classification, and HHS is authorized to fund studies to support those scientific decisions.
Researchers, laboratory workers, and others handling small or trace amounts face heightened risk of criminalization because broadly worded structural scheduling can place any amount of a fentanyl-related substance in Schedule I and regulatory scope may catch research compounds or contamination.
Many people arrested for possession or distribution could face harsher mandatory-minimum sentences due to new weight thresholds (e.g., 40 g / 10 g triggers), likely increasing incarceration, correctional costs for taxpayers, and exacerbating racial and socioeconomic sentencing disparities.
Narrowing analogue coverage by tying it to specific schedules or HHS actions risks enforcement gaps because unlisted but toxic fentanyl-related substances could evade the classifications, and traffickers may substitute excluded compounds, undermining overdose-prevention efforts.
Based on analysis of 9 sections of legislative text.
Adds a permanent class Schedule I for defined fentanyl‑related substances, revises weight triggers for sentencing/import, creates an HHS rescheduling process, eases certain research registration steps, and allows limited post‑conviction relief.
Creates a permanent, class‑wide Schedule I listing for chemicals defined as “fentanyl‑related substances,” requires the Attorney General to publish a list of covered substances, and excludes those classed substances from certain quantity‑based mandatory‑minimum penalties. The bill also narrows which analogues trigger enhanced weight‑based mandatory minimums for trafficking and import/export, establishes an expedited HHS-driven rescheduling/removal process, and adds a limited post‑conviction relief pathway when a listed substance is later rescheduled or removed. The measure further creates an alternative, time‑bound registration pathway for Schedule I research with procedural deadlines, requires the Attorney General to issue implementing rules, and directs the GAO to report after four years on the effects of the class scheduling on research, trafficking, sentencing, and public safety outcomes.